Company profile: Adelia Therapeutics
1.1 - Company Overview
Company description
- Provider of a drug discovery platform developing proprietary tryptamine-based therapeutics to treat central nervous system (CNS) disorders.
Products and services
- Drug Discovery Platform: architects a research-grade platform dedicated to developing proprietary therapeutics from tryptamine compounds, specifically targeting treatment of central nervous system disorders
- Proprietary Tryptamine-Based Therapeutics: engineers custom-engineered CNS-targeted therapeutics built on tryptamine chemistry, developed within the platform to address central nervous system disorders with proprietary compound designs
- CNS Tryptamine Therapeutics Development: constructs platform-based development programs that produce proprietary tryptamine-derived therapeutics for central nervous system disorders, focusing on creating candidates specifically intended to treat CNS conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adelia Therapeutics
Cenes
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical products, developing and commercializing drugs for pain control, sedation, and other central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cenes company profile →
Concentric Medical
HQ: United States
Website
- Description: Provider of minimally invasive medical devices for use in the neurovasculature, focusing on the design, development, and commercialization of these technologies; headquartered in Mountain View, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Concentric Medical company profile →
Centrexion Therapeutics
HQ: United States
Website
- Description: Provider of late clinical-stage biopharmaceutical therapies for chronic pain, including CNTX-4975, a synthetic trans-capsaicin injected directly into the site of pain to treat moderate to severe knee osteoarthritis, targeting the TRPV1 receptor to selectively inactivate local pain fibers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centrexion Therapeutics company profile →
Mika Pharma
HQ: Germany
Website
- Description: Provider of innovative drug delivery technologies for pharmaceuticals, developing, producing, and selling dermal, transdermal, and buccal application systems based on sprayable liposomes, pre-liposomal solutions, and proprietary micellar solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mika Pharma company profile →
Addex Therapeutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage, orally available small-molecule allosteric modulators. Pipeline includes ADX71149, an mGlu2 positive allosteric modulator in Phase 2 for epilepsy; dipraglurant, an mGlu5 negative allosteric modulator for post-stroke/TBI sensorimotor recovery; and GABAB PAM programs for substance use disorder (licensed to Indivior) and chronic cough.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Addex Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adelia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adelia Therapeutics
2.2 - Growth funds investing in similar companies to Adelia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adelia Therapeutics
4.2 - Public trading comparable groups for Adelia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →